Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

We recently published a list of Jim Cramer Discussed These 18 Stocks As Inflation Dropped. In this article, we are going to ...

This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

Equities researchers at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Eli Lilly and ...

Wall Street stocks were in the green at the close of trading on Friday as traders prepped for a three-day break.

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...